Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948540 | 0.89 | OPRM1 (0.37) | OPRM1CHRM2CHRM3SIGMAR1CHRM4 | |
| SCHEMBL948386 | 0.83 | OPRM1 (0.39) | OPRM1CHRM2CHRM3SIGMAR1CHRM4 | |
| SCHEMBL6014982 | 0.81 | OPRM1 (0.47) | OPRM1CHRM2CHRM3SIGMAR1CHRM4 | |
| SCHEMBL949665 | 0.79 | UBE2M (0.42) | OPRM1CHRM2CHRM3SIGMAR1 | |
| SCHEMBL949904 | 0.74 | OPRM1 (0.42) | OPRM1CHRM2CHRM3SIGMAR1KCNH2 | |
| SCHEMBL949606 | 0.73 | OPRM1 (0.39) | OPRM1CHRM2CHRM3SIGMAR1CHRM4 | |
| SCHEMBL948614 | 0.72 | ACHE (0.44) | OPRM1CHRM2CHRM3SIGMAR1KCNH2 | |
| SCHEMBL948316 | 0.71 | OPRM1 (0.46) | OPRM1CHRM2CHRM3SIGMAR1CHRM4 | |
| SCHEMBL949385 | 0.71 | SIGMAR1 (0.41) | OPRM1CHRM2CHRM3SIGMAR1KCNH2 | |
| SCHEMBL948166 | 0.71 | OPRM1 (0.39) | OPRM1CHRM2CHRM3SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | OPRM1 64/4885CHRM2 576/4885CHRM3 1166/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | OPRM1 90/4885CHRM2 1002/4885CHRM3 1727/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | OPRM1 320/4885CHRM2 855/4885CHRM3 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.